Loading
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).
Ga-68 DOTATATE (Netspot, kit) approved June 2016; Cu-64 DOTATATE (Detectnet, 12.7-hour half-life allows central production) approved September 2020; Ga-68 DOTATOC (2019, academic). Changes management in about a third of patients; required before Lu-177 DOTATATE (Lutathera). Also images meningioma and paraganglioma.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Radiolabelled somatostatin analogue binding SSTR2 on neuroendocrine tumours; PET replaces the older In-111 octreotide SPECT with higher sensitivity and same-day imaging. Connects to Somatostatin receptor 2.
1.Gallium-68 DOTATATE (and Cu-64 DOTATATE) slips into a pocket on Somatostatin receptor 2.
Diagnostic radiopharmaceutical billed with the PET/CT scan under Part B for neuroendocrine tumours (Netspot, Detectnet).
Covered for neuroendocrine tumour staging and Lutathera eligibility with prior authorisation of the PET scan.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · Medicare.gov: Diagnostic non-laboratory tests (imaging). Not medical or financial advice; verify with your plan.
Sources: NICE search: gallium-68 DOTATATE PET. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2016 | PET localisation of SSTR-positive neuroendocrine tumours (Ga-68 DOTATATE) |
| US | 2020 | Same (Cu-64 DOTATATE) |
| EU | 2017 | SomaKit TOC (Ga-68 DOTATOC) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Gallium-68 DOTATATE" OR ABSTRACT:"Gallium-68 DOTATATE" OR TITLE:"and Cu-64 DOTATATE" OR ABSTRACT:"and Cu-64 DOTATATE" OR TITLE:"Netspot" OR ABSTRACT:"Netspot" OR TITLE:"Detectnet" OR ABSTRACT:"Detectnet") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gallium-68 DOTATATE (and Cu-64 DOTATATE), not a curated reading list.
Shares PET/CT and the tag diagnostic.
Shares PET/CT and the tag diagnostic.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Advanced Accelerator Applications (Novartis), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Theranostics, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2.
Shares Theranostics, Somatostatin receptor 2, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Somatostatin receptor expression by PET (SSTR-positive), Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Small intestinal neuroendocrine tumours.
Shares Somatostatin receptor expression by PET (SSTR-positive), Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.